The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesopohageal cancer by McKernan, M. et al.
  
 
 
 
 
 
McKernan, M. and McMillan, D.C. and Anderson, J.R. and Angerson, 
W.J. and Stuart, R.C. (2008) The relationship between quality of life 
(EORTC QLQ-C30) and survival in patients with gastro-oesopohageal 
cancer. British Journal of Cancer, 98 (5). pp. 888-893. ISSN 0007-0920 
 
 
 
http://eprints.gla.ac.uk/5253/ 
 
Deposited on: 26 March 2009 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
The relationship between quality of life (EORTC QLQ-C30) and survival in patients with 
gastro-oesophageal cancer 
 
Margaret McKernan1, Donald C McMillan1, John R Anderson2, W.J. Angerson1, Robert C 
Stuart1 
 
1.  University Department of Surgery, Royal Infirmary, Glasgow, G31 2ER, UK 
2.  Department of Surgery, Southern General Hospital, Glasgow, G51, UK 
 
Short title:  Quality of life and survival in gastro-oesophageal cancer 
 
  
Keywords: gastro-oesophageal cancer, stage, treatment, quality of life.  
 
Correspondence to: 
Dr Donald C McMillan 
University Department of Surgery, 
Royal Infirmary, 
Glasgow G31 2ER, United Kingdom. 
Tel No. 0141 211 5435 
Fax No. 0141 552 3229 
E-mail  d.c.mcmillan@clinmed.gla.ac.uk 
 1
Abstract 
It remains unclear whether any aspect of quality of life has a role in predicting survival 
in an unselected cohort of patients with gastro-oesophageal cancer.  Therefore the aim of the 
present study was to examine the relationship between quality of life (EORTC QLQ-C30), 
clinico-pathological characteristics and survival in patients with gastro-oesophageal cancer.  
Patients presenting with gastric or oesophageal cancer, staged using the UICC TNM 
classification and who were deemed operable/inoperable between November 1997 and 
December 2002 (n=152) participated in a quality of life study, using the EORTC QLQ-C30 
core questionnaire.  On univariate analysis, age (P<0.01), tumour length (P<0.0001), TNM 
stage (P<0.0001), weight loss (P<0.0001), dysphagia score (P<0.001), performance status (P 
<0.1) and treatment (P<0.0001) were significantly associated with cancer specific survival.  
EORTC QLQ-C30, physical functioning (P<0.0001), role functioning (P<0.001), cognitive 
functioning (P<0.01), social functioning (P<0.0001), global quality of life (P<0.0001), fatigue 
(P<0.0001), nausea/ vomiting (P<0.01), pain (P<0.001), dyspnoea (P<0.0001), appetite loss 
(P<0.0001) and constipation (P<0.05) were also significantly associated with cancer specific 
survival.  On multivariate survival analysis, tumour stage (P<0.0001), treatment (P<0.001) and 
appetite loss (P<0.0001) were significant independent predictors of cancer specific survival.  
The present study highlights the importance of quality of life (EORTC QLQ-C30) measures, in 
particular appetite loss, as a prognostic factor in these patients.  
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Introduction 
Gastro-oesophageal cancer is the third commonest cause of cancer death in the UK.  Each year, 
there are approximately 16,500 new cases and over 13,000 deaths attributable to the disease.  
Overall survival is poor with the majority of patients presenting with advanced, inoperable 
disease and less than 15% surviving 5 years (Cancerstats, 2004;).  Although there have been 
improvements in survival following surgery (Ando et al., 2000; Hundahl et al., 2000; 
Hofstetter et al., 2002; von Rahden et al., 2004), for the majority of patients current treatment 
offers little in terms of improved survival.  As a result quality of life in these patients is likely 
to be of considerable importance (Aaronson, Bullinger and Ahmedzai, 1988; Aaronson et al., 
1993).
 
The European Organisation for Research and Treatment of Cancer have developed and 
validated the EORTC-QLQ-C30 questionnaire designed to assess the quality of life of cancer 
patients (Aaronson et al., 1993).  Disease specific aspects of the questionnaire provide detailed 
information about the patients’ perception of their health.  Moreover, it has been reported that, 
in a few studies, the EORTC QLQ-C30 measurement of quality of life may have prognostic 
value in patients with gastro-oesophageal cancer (Conroy et al., 2006). 
 
Blazeby and co-workers (2001) reported that, in addition to age and TNM stage, physical 
function or emotional function had independent prognostic value in 92 patients with 
oesophageal cancer.  However, treatment (whether or not the patient underwent surgery) was 
not included in the model (Blazeby et al, 2001). 
 
Fang and co-workers (2003) studied 110 patients with squamous oesophageal cancer and 
concluded that there was evidence to support the correlation of patient-reported QOL scores 
with survival; therefore, pre-treatment physical functioning might be a surrogate marker of an 
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unrecognised biological prognostic factor.  Although performance status was significant on 
univariate analysis it was not significant on multivariate analysis, whereas physical functioning 
was significant (Fang et al, 2003). 
 
In contrast, in a study of more than 1000 patients with inoperable gastro-oesophageal cancer, 
entering 3 randomised clinical trials, Chau and colleagues (2004) reported that no aspect of the 
QLQ-C30 had independent prognostic value when performance status was considered.  
However, physical function, role function and global quality of life were associated with 
survival on univariate analysis.  There were no survival differences among patients with 
oesophageal or gastric cancer (Chau et al, 2004).  However, this study was retrospective and 
included selected cohorts of patients. 
 
Therefore, from the above it remains unclear whether any aspect of quality of life other than 
physical function has a role in predicting survival in an unselected cohort of patients with 
gastro-oesophageal cancer.  The aim of the present study was to examine the relationship 
between quality of life (EORTC QLQ-C30), clinico-pathological characteristics and survival in 
patients with gastro-oesophageal cancer 
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PATIENTS AND METHODS 
Patients 
Patients presenting with adenocarcinoma or squamous carcinoma of the gastric or oesophageal 
tract  at the Royal Infirmary and Southern General Hospital, Glasgow between November 1997 
and December 2002 (n=152) participated in a quality of life study, using the EORTC QLQ-
C30 core questionnaire.  
 
The extent of tumour spread was recorded using the TNM 5th edition classification (Sobin and 
Wittekind, 1997).  Tumours around the gastro-oesophageal junction were further classified 
according to tumour site, using the Siewert system; type 1 and 2 lesions of the gastro-
oesophageal junction were designated as cancers of the oesophagus.  Type 3 tumours of the 
cardia were designated as gastric cancers (Siewert and Stein, 1998).  For gastric cancers, 
tumour node metastasis (TNM) stage I–III tumours were considered to be amenable to curative 
surgical resection.  In the present study for oesophageal cancers, TNM stage I–III tumours, 
excluding T4, were deemed to be amenable to curative surgical resection.  
 
Patients who had stage 1 and 2 disease but their performance status was poor were not deemed 
suitable for surgery and went forward for active palliative treatment or supportive care.  There 
were 152 patients included in the study, 69 patients were suitable for surgery and 83 patients 
were inoperable. 
 
The study was approved by the Research Ethics Committee of the Royal Infirmary and 
Southern General Hospital, Glasgow. 
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Methods 
Clinical and demographic variables were recorded at the patient’s initial presentation and 
included age, sex, tumour type, site and length, TNM stage, ECOG performance status, weight 
loss, dysphagia and treatment. 
 
Following diagnosis but prior to treatment the lead clinician approached patients as to whether 
they would participate in a study to examine their quality of life.  If they gave informed consent 
they were given the EORTC QLQ-C30 questionnaire to complete.  / 
 
Different aspects of quality of life were assessed using this cancer specific 30-item 
questionnaire, which has six functional scales (physical, role, emotional, cognitive, social, 
global health status) and several questions relating to a range of physical symptoms (Aaronson 
et al, 1993).  Patients marked to what extent each statement applied to them.  In the present 
study a number of patients were excluded because they were unlikely to understand the 
language, had brain metastases, delirium or confusion.  Neither age nor performance status 
were considered when offering the patient questionnaire.  Patients were not randomised.  Few 
subjects were excluded (less than 10 patients) and therefore in those patients offered the 
questionnaire the bias was likely to be small.
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Statistics 
Scoring algorithms have been produced by the EORTC Quality of Life Study Group.  The sum 
of items in each category is added and the total divided by the number of questions in the 
category.  A linear transformation is then undertaken to convert this to a percentage scale with 
a higher score representing a higher response level.  Thus a high score for functional scale 
represents a high/healthy level of functioning.  A high score for the global health status/quality 
of life represents a high quality of life.  In contrast, a high score for the symptom scale 
represents a higher level of symptoms / problems (Aaronson et al, 1993). 
 
Data are presented as the median and range. Survival was determined from time of biopsy 
proven diagnosis until time of death.  Patients were followed up at their clinic or endoscopy 
appointments until time of death, if patients did not attend appointment, their general 
practitioner was contacted.  Deaths up to April 2007 were included in the analysis.  Univariate 
and multivariate survival analysis and calculation of hazard ratios (HR) were performed using 
a Cox regression model.  Covariates that were significant on univariate analysis were included 
in the multivariate analysis.  This was performed using a stepwise backward procedure to 
derive a final model of the variables that had a significant relationship with survival.  To 
remove a variable from the model, the corresponding P-value had to be greater than 0.05.  
Comparison of the association between tumour site, TNM stage, treatment and the functional 
(physical, role, emotional, cognitive, social, global health status) and physical symptoms 
(fatigue, pain and appetite loss) scales of the EORTC-QLQ-C30 quality of life questionnaire 
was carried out using the X2-test or Mann-Whitney U-test where appropriate.  Analysis was 
performed using SPSS software (SPSS Inc, Chicago, IL, USA). 
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Results 
Patient characteristics and cancer specific survival analysis of patients with gastro-oesophageal 
cancer (n=152) are shown in Table 1.  The minimum follow up period was 54 months or until 
date of death, the median follow up for survivors was 81 months, one patient was lost to follow 
up and one patient withdrew from the study.  During this period 106 (70%) patients died from 
their disease and 14 (9%) died from co-morbid disease.   
 
The relationship between clinico-pathological characteristics, quality of life and cancer specific 
survival in patients with gastro-oesophageal cancer is shown in Table 1  The majority of 
patients were over the age of 65 years (57%), male (68%) and had adenocarcinomas (84%).  
The majority of patients presented with weight loss (66%), had little or no dysphagia, and a 
near normal performance status (ECOG-ps, 71%).  The majority of patients had EORTC QLQ-
C30 function scores above 50 (physical functioning100%, role functioning 65%, emotional 
functioning 74%, cognitive functioning 83%, social a functioning 79% and global quality of 
life 56%) and symptom scores below 50 (fatigue 69%, nausea/vomiting 85%, pain 86%, 
dyspnoea 79%, sleep disturbance 69%, appetite loss 64%, constipation 76%, diarrhoea 95% 
and financial difficulties 89%) and therefore had apparently normal quality of life (Table 1) 
 
The relationship between clinico-pathological characteristics, quality of life and cancer specific 
survival in patients with gastro-oesophageal cancer is shown in Table 1.  On univariate 
analysis, age (P<0.01), tumour length (P<0.0001), TNM stage (P<0.0001), weight loss 
(P<0.0001), dysphagia score (P<0.001), performance status (P <0.1) and treatment (P<0.0001) 
were significantly associated with cancer specific survival.  EORTC QLQ-C30, physical 
functioning (P<0.0001), role functioning (P<0.001), cognitive functioning (P<0.1), social 
functioning (P<0.0001), global quality of life (P<0.0001), fatigue (P<0.0001), nausea/ 
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vomiting (P<0.01), pain (P<0.001), dyspnoea (P<0.0001), appetite loss (P<0.0001) and 
constipation (P<0.05) were also significantly associated with cancer specific survival.  
 
On multivariate analysis, tumour stage (P<0.0001), treatment (P<0.001) and appetite loss 
(P<0.0001) were significantly independent predictors of cancer specific survival.  The 
relationship between appetite loss and cancer specific survival in patients with gastro-
oesophageal cancer is shown in Figure 1.  
 
In the present study C-reactive protein concentrations, at the time of quality of life assessment, 
were available in 94 patients (57 patients <10mg/l, 37 patients >10mg/l) and were significantly 
associated with poorer cancer specific survival (P<0.0001).  Therefore we included C-reactive 
protein in addition to TNM stage, treatment and appetite loss in the multivariate survival 
model.  TNM stage (HR 1.36, 95%CI 1.00-1.85, P=0.0532), treatment (HR 3.72, 95%CI 1.73-
7.99, P=0.0007), appetite loss (HR 1.02, 95%CI 1.01-1.03, P<0.0001) and C-reactive protein 
(HR 2.02, 95%CI 1.12-3.63, P=0.0187) were independently associated with cancer specific 
survival. 
 
The relationship between tumour site, clinico-pathological characteristics and quality of life in 
patients with gastro-oesophageal cancer is shown in Table 2.  Compared with the gastric cancer 
patients, oesophageal cancer patients were older (P<0.01), had more dysphagia (P<0.001) and 
a poorer ECOG-ps (P<0.05).  In terms of quality of life, compared with the gastric cancer 
patients, oesophageal cancer patients had higher emotional functioning (P<0.01), cognitive 
functioning (P<0.05), less nausea and vomiting (P<0.05). 
 
The relationship between TNM stage and clinico-pathological and quality of life characteristics 
in patients with gastric-oesophageal cancer is shown in Table 3.  With increasing TNM stage 
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patients had greater weight loss (P<0.01) and were less likely to have had surgery (P<0.001).  
In terms of quality of life, with increasing TNM stage there was poorer physical functioning 
(P<0.05), emotional functioning (P<0.05), social functioning (P<0.01) and global quality of 
life (P<0.01).  In terms of symptoms, with increasing TNM stage there was more fatigue 
(P<0.01), appetite loss (P<0.001), dyspnoea (P<0.05) and constipation (P<0.05). 
 
The relationship between appetite loss, clinico-pathological characteristics and quality of life in 
patients with gastric-oesophageal cancer is shown in Table 4.  Increasing appetite loss was 
associated with greater tumour length (P<0.05), TNM stage (P<0.001) and the operability of 
the tumour (P<0.001).  Also, increasing appetite loss was associated with weight loss 
(P<0.001) and dysphagia (P<0.001).  In terms of quality of life, increasing appetite loss was 
associated with poorer physical (P<0.001), role (P<0.001), emotional (P<0.01), cognitive 
(P<0.01), social (P<0.001) and global quality of life (P<0.001) functioning.  In terms of 
symptoms, with increasing appetite loss there was more fatigue (P<0.01), nausea and vomiting 
(P<0.001), pain (P<0.001), sleep disturbance (<0.05) and constipation (P<0.001).   
 
The relationship between systemic inflammatory response, as evidenced by elevated C-reactive 
protein, clinico-pathological and quality of life characteristics in patients with gastric-
oesophageal cancer is shown in Table 5.  An elevated C-reactive protein was associated with 
greater tumour length (P<0.01), advanced TNM stage (P<0.01) and the operability of the 
tumour (P<0.001) and a poorer ECOG-ps (P<0.05).  In terms of quality of life, an elevated C-
reactive protein was associated with poorer physical (P<0.01), role (P<0.05) and social 
(P<0.05) functioning.  In terms of symptoms, with an elevated C-reactive protein was 
associated with more fatigue (P<0.01), pain (P<0.05) and appetite loss (P<0.01).   
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Discussion 
In the present study tumour site was not associated with major differences in EORTC QLQ-
C30 quality of life function or symptom scores.  However, there were major differences with 
increasing stage of disease.  Nevertheless, the symptom score for appetite loss remained 
significant prognostic factor even after adjustment for TNM stage.  Furthermore, when the 
relationship between appetite loss and the other quality of life function or symptom scores was 
examined it was clear that appetite loss was closely related to these measures.  Taken together 
the results of the present study highlight the importance of appetite loss as a presenting 
symptom in patients with gastro-oesophageal cancer. 
 
Few studies have examined the relationship between aspects of quality of life and survival in 
patients with gastro-oesophageal cancer.  The results of the present study are consistent with 
the report of Fang and co-workers (2003) who reported that appetite loss was associated with 
poorer survival in 110 patients with oesophageal cancer.  However, the association was much 
weaker than that of the present study and was not significant in multivariate analysis.  
Furthermore, the follow-up period and the numbers of patients who died of their disease was 
not defined.  Blazeby and colleagues (1995), in a smaller study of 59 patients with oesophageal 
cancer, also reported that appetite loss was associated with poorer survival (Blazeby et al, 
1995) 
 
The basis of the relationship between appetite loss and poorer cancer specific survival cannot 
be determined by the present cross sectional study.  However, it was of interest that appetite 
loss was closely associated with nausea and vomiting, dysphagia and weight loss and therefore 
it may be that these symptoms result in appetite loss and the consequent loss of weight, which 
has long been recognised to impact on outcome (DeWys et al, 1980).   
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A number of workers have implicated the systemic inflammatory response in this process 
(Kotler, 2000; MacDonald, 2007).  O’Gorman and co-workers (1998), in a cross sectional 
study, showed that in addition to appetite loss and weight loss, the systemic inflammatory 
response was an important factor in determining patients’ quality of life (EORTC QLQ-C30) in 
gastro-intestinal cancer patients (O’Gorman et al, 1998).  Therefore, it is of interest that two 
recent studies have shown that the presence of a systemic inflammatory response, as evidenced 
by an elevated C-reactive protein, predicts survival in both operable (Crumley et al, 2006a) and 
inoperable (Crumley et al, 2006b) gastro-oesophageal cancer patients.  In the present study C-
reactive protein concentrations, at the time of quality of life assessment, were available in 94 
(62%) patients.  Consistent with previous work an elevated C-reactive protein concentration 
was associated with increased appetite loss and when included in the multivariate analysis, an 
elevated C-reactive protein concentration was independently associated with poorer cancer 
specific survival.  However, even those patients without an elevated C-reactive protein 
concentration reported some appetite loss and the independent prognostic value of appetite loss 
remained, thus confirming the importance of appetite loss in the multifactorial nature of weight 
loss and poor outcome in these patients (MacDonald, 2007). 
 
In summary, in patients with gastro-oesophageal cancer, routinely used prognostic factors are 
based predominantly on clinical and pathological findings.  The present study highlights the 
importance of quality of life (EORTC QLQ-C30) measures, in particular appetite loss, as 
prognostic factors in these patients.    
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Table 1. The relationship between clinico-pathological characteristics, quality of life and cancer specific survival in patients with gastro-
oesophageal cancer (n=152) 
 Patients  Univariate analysis
(n=152) HR     (95%CI)
P-value Multivariate analysis
HR    (95%CI)
P-value 
Age:(<65/65-74/≥75) 66/56/30 1.46 (1.13-1.88) 0.0033  
Sex:(male/female)     
      
    
  
   
 
  
    
104/48 0.84 (0.55-1.30) 0.4377
Tumour type:(adeno/squam) 127/25 1.40 (0.83-2.36) 0.2016
Tumour site:(oesoph/gastric) 70/82 0.88 (0.60-1.29) 0.5163   
Tumour length:(<5/510/>10cm) 
 
60/70/12 2.37 (1.71-3.27) <0.0001
TNM stage:(I/II/III/IV) 28/46/34/41 2.28 (1.84-2.83) <0.0001 1.74 (1.36-2.23) <0.0001
Weight loss:(yes/no) 101/51 3.08 (1.94-4.89) <0.0001   
Dysphagia score:(1/2/3/4/5) 
 
81/23/32/15/1 1.37 (1.57-1.62) 0.0003   
ECOG:(0-1/2/3-4) 108/38/6
 
 1.60 (1.39-2.27) 0.0069
Treatment:(operable/inoperable)
 
69/83 7.52 (4.68-12.07) 
  
<0.0001 3.61 (2.00-6.53) 
 
<0.0001
EORTC QLQ-C30 (0-100)      
Physical functioning 93 (66.7-100) 0.96 (0.94-0.98) <0.0001
Role functioning 66.7 (0-100) 0.99 (0.99-1.00) 0.0006   
Emotional functioning 66.7 (0-100 1.00 (0.99-1.00) 0.1377   
Cognitive functioning 83.3 (0-100) 0.99 (0.98-0.99) 0.0045   
Social functioning 83.3 (0-100) 0.99 (0.98-1.00) <0.0001   
Global quality of life 50 (0-100) 0.98 (0.97-0.99)  <0.0001   
Fatigue 33.3 (0-100) 1.02 (1.01-1.02) <0.0001   
Nausea and vomiting 16.7 (0-100) 1.01 (1.00-1.01) 0.0050   
Pain 16.7 (0-100) 1.01 (1.01-1.02) 0.0002   
Dyspnoea 0 (0-100) 1.01 (1.00-1.02) <0.0001   
Sleep disturbance 33.3 (0-100) 1.00 (0.99-1.01) 0.1558   
Appetite loss 33.3 (0-100) 1.02 (1.02-1.03) <0.0001 1.02 (1.01-1.02) <0.0001
Constipation 33.3 (0-100) 1.01 (1.00-1.01) 0.0261   
Diarrhoea 0 (0-100) 1.00 (0.99-1.01) 0.9586   
Financial difficulty 0 (0-100) 1.00 (0.99-1.01) 0.4626   
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Table 2. The relationship between tumour site, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer 
(n=152) 
 Gastric 
(n=82)
Oesophageal 
(n=70)
P-value
Age:(<65 yrs/ 65-74yrs/>75 yrs) 41/29/12 25/27/18 0.0041
Sex:(male/female) 53/29   
    
  
   
    
  
51/19 0.279
Type:(squam/adeno) 1/81 24/46 <0.001
Tumour length:(<5cm/5-10cm/>10cm) 
 
33/33/7 27/37/5 0.724 
Tumour stage:(I/II/III/IV) 22/13/18/28 6/33/16/13 0.528
Dysphagia score:(1/2/3/4/5) 64/9/8/1/0 17/14/24/1 <0.001 
Weight loss:(yes/no) 53/29 48/22 0.610 
ECOG:(0-1/2/3-4) 64/17/1 44/21/5 0.018
Treatment:(operable/inoperable)
 
37/45 32/38
 
0.942
EORTC QLQ-C30 (0-100)    
Physical functioning 93.3 (66.7-100) 93.3 (66.7-100) 0.733 
Role functioning 66.7 (0-100) 66.7 (0-100) 0.923 
Emotional functioning 66.7 (0-100) 83.3 (0-100) 0.007 
Cognitive functioning 83.3 (0-100) 83.3 (0-100) 0.038 
Social functioning 83.3 (0-100) 75 (0-100) 0.964 
Global quality of life 50 (0-100) 50 (0-100) 0.284 
Fatigue 33.3 (0-100) 22.2 (0-100) 0.077 
Nausea and vomiting 16.7 (0-100) 0 (0-100) 0.036 
Pain 16.7 (0-100) 16.7 (0-100) 0.716 
Dyspnoea 33.3 (0-100) 0 (0-100) 0.123 
Sleep disturbance 33.3 (0-100) 33.3 (0-100) 0.360 
Appetite loss 33.3 (0-100) 33.3 (0-100) 0.624 
Constipation 33.3 (0-100) 33.3 (0-100) 0.031 
Diarrhoea 0 (0-100) 0 (0-100) 0.802 
Financial difficulty 0 (0-100) 0 (0-66.7) 0.098 
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Table 3. The relationship between TNM stage and clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer 
(n=152) 
 TNM I  
(n=28)
TNM II 
(n=46)
TNM III 
(n=34)
TNM IV 
(n=41)
P-value
Age:(<65 yrs/ 65-74yrs/>75 yrs) 15/12/1 23/21/2 18/9/7 18/13/10 0.482
Sex:(male/female) 17/11     
      
      
     
     
     
     
      
     
       
33/13 20/14 31/10 0.387
Tumour type:(squam/adeno) 2/26 13/33 6/28 4/37 0.576
Tumour site:(oesophagus/gastric) 6/22 33/13 16/18 13/28 0.528
Tumour length:(<5cm/5-10cm/>10cm)
 
 19/7/0 21/22/3 10/19/3 8/22/6 <0.001
Weight loss:(yes/no) 14/14 29/17 23/11 34/7 0.004
Dysphagia score:(1/2/3/4/5) 
 
22/3/3/0/0 20/10/9/7/0 14/5/9/5/1 23/5/10/3/0 0.130
ECOG:(0-1/2/3-4) 22/6/0 33/11/2 27/6/1 24/15/2 0.099
Treatment:(operable/inoperable)
 
24/4 26/20 16/18 1/40 <0.001
EORTC QLQ-C30 (0-100)
Physical functioning 93.3 (73.3-100) 100 (66.7-100) 100 (73.3-100) 86.7 (66.7-100) 0.023 
Role functioning 66.7 (0-100) 66.7 (0-100) 66.7 (0-100) 50 (0-100) 0.058 
Emotional functioning 66.7 (8.3-100) 75 (25-100) 83.3 (0-100) 58.3 (0-100) 0.042 
Cognitive functioning 83.3 (50-100) 83.3 (33.3-100) 83.3 (16.7-100) 75 (0-100) 0.042 
Social functioning  100 (33.3-100) 83.3 (0-100) 66.7 (0-100) 50 (0-100) 0.002 
Global quality of life 66.7 (8.3-100) 66.7 (0-100) 50 (16.7-100) 41.7 (0-100) 0.001 
Fatigue 27.8 (0-66.7) 22.2 (0-88.9) 33.3 (0-100) 55.6 (0-100) 0.002 
Nausea and vomiting 16.7 (0-100) 0 (0-100) 16.7 (0-100) 16.7 (0-100) 0.553 
Pain 16.7 (0-66.7) 16.7 (0-100) 33.3 (0-100) 16.7 (0-100) 0.098 
Dyspnoea 16.7 (0-100) 0 (0-100) 0 (0-100) 33.3 (0-100) 0.014 
Sleep disturbance 33.3 (0-100) 33.3 (0-100) 33.3 (0-100) 66.7 (0-100) 0.689 
Appetite loss 0 (0-100) 33.3 (0-100) 33.3 (0-100) 66.7 (0-100) <0.001 
Constipation 33.3 (0-66.7) 16.7 (0-100) 0 (0-100) 33.3 (0-100) 0.013 
Diarrhoea 0 (0-100) 0 (0-100) 0 (0-33.3) 0 (0-66.7) 0.601 
Financial difficulty 0 (0-66.7) 0 (0-100) 0 (0-66.7) 0 (0-100) 0.306 
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Table 4.The relationship between appetite loss, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer 
(n=152) 
 Not at all 
(n=55)
A little  
(n=43)
Quite a bit 
(n=26)
Very much 
(n=28)
P-value
Age:(<65 yrs/ 65-74yrs/>75 yrs) 27/18/10 18/15/10 8/15/3 13/8/7 0.540
Sex:(male/female) 43/12     
      
      
     
  
      
     
    
      
     
       
   
26/17 15/11 20/8 0.312
Tumour type:(squam/adeno) 7/48 5/38 7/19 6/22 0.138
Tumour site:(oesophagus/gastric) 25/30 17/26 15/11 13/15 0.603
Tumour length:(<5cm/5-10cm/ >10cm)
 
 27/20/4 18/21/2 9/15/2 6/14/4 0.016
TNM stage:(I/II/III/IV) 16/17/13/8 8/17/9/9 3/8/7/8 1/4/5/16 <0.001
Weight loss:(yes/no) 26/29 27/16 22/4 26/2 <0.001
Dysphagia score:(1/2/3/4/5) 
 
37/10/6/2/0 24/6/10/3/0
 
9/4/9/3/1 11/3/7/7/0 <0.001
ECOG:(0-1/2/3-4) 39/14/2 34/8/1 18/7/1 17/9/2 0.281
Treatment:(operable/inoperable)
 
35/20 20/23 11/15 3/25 <0.001
EORTC QLQ-C30 (0-100)
Physical functioning 100 (73.3-100)  100 (73.3-100) 86.7 (66.7-100) 80 (66.7-100) <0.001 
Role functioning 100 (0-100) 66.7 (0-100) 58.3 (0-100) 33.3 (0-100) <0.001 
Emotional functioning 75 (73.3-100) 66.7 (0-100) 83.3 (8.3-100) 58.3 (0-96.7) 0.003 
Cognitive functioning 83.3 (16.7-100) 83.3 (0-100) 83.3 (50-100) 66.7(0-100) 0.001 
Social functioning 100 (0-100)  83.3 (0-100) 66.7 (0-100) 50 (0-100) <0.001 
Global quality of life 66.7 (16.7-100) 50 (0-100) 45.8(16.7-100) 29.1 (0-66.7) <0.001
Fatigue 11.1 (0-88.9) 33.3 (0-83.2) 33.3 (0-100) 77.7 (22.2-100) <0.001 
Nausea and vomiting 0 (0-100) 16.7 (0-100) 16.7 (0-100) 41.7 (0-100) <0.001 
Pain 16.7 (0-100) 16.7 (0-83.3) 33.3 (0-100) 25 (0-100) <0.001 
Dyspnoea 0 (0-66.7) 0 (0-100) 0 (0-100) 50 (0-100) <0.001 
Sleep disturbance 0 (0-100) 33.3 (0-100) 33.3 (0-100) 33.3 (0-100) 0.044 
Constipation 0 (0-100) 33.3 (0-100) 33.3 (0-100) 66.7 (0-100) <0.001 
Diarrhoea 0 (0-100) 0 (0-66.7) 0 (0-100) 0 (0-100) 0.512 
Financial difficulty 0 (0-66.7) 0 (0-100) 0 (0-100) 0 (0-100) 0.296 
 
 19
Table 5: The relationship between systemic inflammatory response, as evidenced by elevated C-reactive protein, clinico-pathological and quality of 
life characteristics in patients with gastric-oesophageal cancer (n=94) 
 CRP<10 
(n=57)
CRP>10 
(n=37)
P value
Age:(<65 yrs/65-74yrs/>75yrs)  34/16/7 18/12/7 0.258
Sex:(male/female) 38/19 27/10 0.520 
 
  
  
    
 
    
Tumour type:(adeno/squam) 48/9 30/7 0.695 
Tumour site:(oesoph/gastric) 23/34 20/17 0.195 
Tumour length:(<5cm/5-10cm/>10cm) 
 
35/17/2 11/20/3 0.005 
Tumour stage:(I/II/III/IV) 15/20/13/8 4/10/10/13 0.006
Weight loss:(yes/no) 31/16 27/10 0.072 
Dysphagia score:(1/2/3/4/5) 29/14/11/3/0 18/6/10/2/1 0.390
ECOG:(0-1/2/3-4) 52/5/0 27/10/0 0.019
Treatment:(operable/inoperable)
 
40/17 8/29
 
<0.001
 
EORTC:(0-100)
Physical functioning 100 (73-100) 86.7 (66.7-100) 0.001 
Role functioning 66.7 (0-100) 66.7 (0-100) 0.040 
Emotional functioning 66.7 (0-100) 70.8 (0-100) 0.343 
Cognitive functioning 83.3 (16.7-100) 83.3 (33.3-100) 0.875 
Social functioning 83.3 (0-100) 66.7 (0-100) 0.045 
Global quality of life 66.7 (0-100) 50 (0-100) 0.068 
Fatigue 33.3 (0-100) 44.4 (0-88.9) 0.003 
Nausea and vomiting 16.7 (0-100) 16.7 (0-100) 0.152 
Pain 16.7 (0-100) 16.7 (0-100) 0.040 
Appetite loss 33.3 (0-100) 66.7 (0-100) 0.001 
Dyspnoea 0 (0-100) 0 (0-100) 0.055 
Sleep disturbance 33.3 (0-100) 33.3 (0-100) 0.518 
Constipation 0 (0-100) 33.3 (0-100) 0.142 
Diarrhoea 0 (0-66.7) 0 (0-100) 0.304 
Financial difficulty 0 (0-100) 0 (0-100) 0.362 
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Figure 1.  The relationship between appetite loss (None, A little, Quite a bit, Very much, from 
top to bottom) and cancer specific survival in patients with gastro-oesophageal cancer. 
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